Prostamax
Prostate Research only Animal studies Synthetic short peptide (Cytogen)
Also called KEDP peptide
A four-amino-acid Khavinson peptide associated with the prostate. In rats with chronic prostatitis it reduced swelling and inflammation, and in cell studies it loosened packed chromatin in lymphocytes from older adults.
Evidence at a glance
- Evidence
- Animal studies — Not yet studied in people
- Status
- Research compound only
- Dosing
- No human study has set a dose
Animal and cell data from one group.
What studies report
- Reduced swelling and inflammation in rats with chronic prostatitis
- Loosened chromatin in lymphocytes from older adults
How it works
A Khavinson short peptide: at two to four amino acids it is small enough to pass through cell and nuclear membranes intact. The proposed mechanism is that it binds specific sites on nuclear DNA and changes which genes are switched on in its target tissue, rather than acting on a surface receptor the way most peptides do.
Where it acts
ProstateThe library groups this compound under Prostate. The diagram shows that target, not every tissue it reaches.
Illustrated
AI-generated subject illustration; not a depiction of the compound or evidence of its effects.
Why people take it
Reasons people seek it out — not a list of proven effects.
Status: Animal and cell data, mostly from one research group.
- Route
- Subcutaneous injection, or oral capsule depending on the preparation
- Sequence
- Lys-Glu-Asp-Pro
- Formula
- C20H33N5O9
- Molecular weight
- 487.5 g/mol
- Available as
- 20 mg
Search PubMed for Prostamax → We link a live search rather than a fixed citation list, so it stays current and nothing here is a reference we have not checked.
Educational information only. Nothing here is medical advice, a dosing protocol, or a recommendation to use any compound. Most entries describe substances not approved for human use. Talk to a licensed clinician before acting on anything you read here. How to read these entries.